

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
19964	12/LO/1289	107457	PROUD	Number Agreed	30	30	Date Agreed	30/04/2014	24	04/01/2017	24	Recruitment Finished
19965	12/SC/0592	98570	ROSE	Number Agreed	30	30	Date Agreed	31/01/2016	32	05/01/2017	32	Recruitment Finished
19966	16/SC/0351	205155	A Phase III, open-label, multicenter, three-arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy vs. regorafenib in patients with previously treated unresectable locally advanced or metastatic colorectal cancer	Number Agreed	5	5	Date Agreed	16/04/2019	5	25/01/2017	5	Recruitment Finished
19969	13/NI/0148	102251	OCS Sparing Study	Number Agreed	12	12	Date Agreed	27/05/2018	10	06/03/2017	10	Recruitment Finished
19971	12/WMM/0340	111557	UK FixDT	Number Agreed	4	4	Date Agreed	31/12/2016	2	23/02/2017	2	Recruitment Finished
19972	12/EM/0321	112490	ALT, and HDL for Identifying Lysosomal Acid Lipase Deficiency	Number Agreed	50	50	Date Agreed	31/03/2016	188	23/02/2017	188	Recruitment Finished
19999	15/SC/0667	173734	LENS Study	Number Agreed	40	40	Date Agreed	31/10/2016	27	30/03/2017	27	Recruitment Finished